Home » Newsletters » BioWorld Science

BioWorld Science

June 22, 2012

View Archived Issues

Promising data disclosed on novel PD-1/PD-L1-blocking cancer immunotherapies

Novel calcium-sensing receptor agonists designed by Leo Pharma

Novel MMP inhibitors disclosed by Janssen Pharmaceutica

CDC updates recommendations on pneumococcal vaccination in adults with immunocompromising conditions

Drug marketed for infertility shows promise to treat rheumatoid arthritis

NNC0109-0012 evaluated in phase I and II trials

New product reduces levodopa-induced dyskinesia while maintaining antiparkinsonian benefit

Novel diagnostics for cancer disclosed by French team

Lupin presents novel candidate diabetes therapies

Scioderm reports phase II data for topical SD-101

Oncomatrix and National Jewish Health join forces to treat invasive tumors

New GPR119 receptor agonists patented by Pfizer

Collaborating organizations design new GM-CSF-targeting products

CSHL announces new partnership for next-generation shRNA library

IRM and Novartis team up to design novel FGF-21 variants

Ampio Pharmaceuticals updates on Zertane pre-IND meeting

Stem cell product enters trial in dry age-related macular degeneration

Phrixus Pharmaceuticals receives NIH award

OncoEthix in-licenses product from Mitsubishi Tanabe Pharma

MicroDose Therapeutx and Moerae Matrix to develop drug for IPF

Lyrica indications expanded in Japan and U.S.

Celgene provides regulatory update on lenalidomide and pomalidomide

MSD obtains approval for Renivace in new indication

Novo Nordisk to begin phase III program for once-weekly GLP-1 analogue

Gentium responds to EMA's questions regarding defibrotide MAA

Japanese authorities approve calcium channel blocker for pediatric hypertension

GSK launches controlled-release Paxil formulations in Japan

ACE inhibitor approved in Japan to treat pediatric hypertension

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 29, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 29, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact
BioWorld
Shionogi & Co. Ltd. will acquire global rights to U.S. FDA approved amyotrophic lateral sclerosis therapy edaravone through a $2.5 billion acquisition deal with...
Big pharma taps fast Asia innovation in search of next Keytruda
BioWorld
Speed and innovation from Asia Pacific’s (APAC) biotechnology sector had big pharma scouring the region for the next oncology heir to Keytruda (pembrolizumab),...